Repligen Corporation
HealthcareNASDAQ:RGEN · NASDAQ Global Select
-$2.74 today
Vol 1.27M · Avg 1.08M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$763.3M of revenue converted into $51.4M of net income for the selected period. Gross margin is 50.3% and net margin is 6.8%, showing how much revenue survives after costs and taxes. EPS is $0.90, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $738.3M +16.4% | $634.4M +0.3% | $632.4M -21.1% | $801.5M +19.5% | $670.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $390.6M +8.6% | $359.8M +1.7% | $353.9M +2.3% | $345.8M +23.8% | $279.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $347.6M +26.6% | $274.6M -1.4% | $278.4M -38.9% | $455.7M +16.5% | $391.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 47.1% +3.8pp | 43.3% -0.7pp | 44.0% -12.8pp | 56.9% -1.5pp | 58.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $54.2M +25.4% | $43.2M +1.1% | $42.7M -2.8% | $43.9M +28.2% | $34.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $290.5M +10.3% | $263.4M +20.5% | $218.6M +1.3% | $215.8M +17.4% | $183.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $288.0M -7.0% | $309.8M +34.2% | $230.7M -0.1% | $231.0M +3.1% | $224.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $78.7M -9.0% | $86.6M +0.5% | $86.1M +51.0% | $57.0M +48.3% | $38.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | $164.3M +104.7% | $80.3M -44.8% | $145.3M -47.6% | $277.3M +36.4% | $203.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 22.3% +9.6pp | 12.7% -10.3pp | 23.0% -11.6pp | 34.6% +4.3pp | 30.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | $59.6M +269.7% | -$35.1M -173.6% | $47.7M -78.8% | $224.7M +34.3% | $167.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 8.1% +13.6pp | -5.5% -13.1pp | 7.5% -20.5pp | 28.0% +3.1pp | 24.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $27.6M | $0 | $0 -100.0% | $7.0M +3864.8% | $176.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $23.2M +2.7% | $22.6M +125.2% | $10.0M +236.8% | $3.0M -76.6% | $12.7M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $2.8M -65.3% | $8.1M -10.3% | $9.0M +262.8% | -$5.5M +59.7% | -$13.7M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $62.4M +330.7% | -$27.0M -147.7% | $56.7M -74.1% | $219.1M +42.7% | $153.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 8.5% +12.7pp | -4.3% -13.2pp | 9.0% -18.4pp | 27.3% +4.4pp | 22.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $13.5M +986.9% | -$1.5M -107.2% | $21.1M -36.4% | $33.2M +31.4% | $25.3M | $1.3B | -$1.6B | $745.2M |
| Net Income | $48.9M +291.6% | -$25.5M -171.7% | $35.6M -80.9% | $186.0M +45.0% | $128.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | 6.6% +10.6pp | -4.0% -9.7pp | 5.6% -17.6pp | 23.2% +4.1pp | 19.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 +289.1% | -$0 -171.9% | $1 -80.9% | $3 +43.8% | $2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 +287.0% | -$0 -173.0% | $1 -80.6% | $3 +44.6% | $2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $56.2M +0.5% | $55.9M +0.4% | $55.7M +0.5% | $55.5M +0.8% | $55.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $56.6M +1.1% | $55.9M -0.8% | $56.4M -1.9% | $57.5M +0.3% | $57.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.40B
Globus Medical, Inc.
NYSE:GMED
$10.84B
Baxter International Inc.
NYSE:BAX
$10.77B
Masimo Corporation
NASDAQ:MASI
$9.42B
Charles River Laboratories International, Inc.
NYSE:CRL
$9.03B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.73B
AptarGroup, Inc.
NYSE:ATR
$7.51B
Avantor, Inc.
NYSE:AVTR
$6.41B
Stevanato Group S.p.A.
NYSE:STVN
$4.66B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does RGEN generate?
Repligen Corporation (RGEN) reported $738.26M of revenue in fiscal 2025.
Is RGEN profitable?
Repligen Corporation (RGEN) reported $48.89M of net income, with a net margin of 6.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.